Clinical Trials Logo

Clinical Trial Summary

After confirming eligibility, a single subject with four selected target lesions will receive both ALLO-ASC-SHEET and Vehicle control, three target lesions for ALLO-ASC-SHEET and the other target for Vehicle control, and which lesion to apply which IP treatment will be determined randomly at the time of enrollment using pre-designed block randomization scheme.


Clinical Trial Description

Primary efficacy endpoint will be assessed during and after 12th IP applications. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05157958
Study type Interventional
Source Anterogen Co., Ltd.
Contact Fernanda Bellodi Schmidt
Phone 82-2-2014-0391
Email antstudy@anterogen.com
Status Recruiting
Phase Phase 2
Start date May 1, 2023
Completion date April 28, 2026

See also
  Status Clinical Trial Phase
Completed NCT03536143 - A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients Phase 1/Phase 2
Recruiting NCT04917887 - Long-Term Follow-up Protocol
Completed NCT04917874 - A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa Phase 3
Terminated NCT03578029 - Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa Phase 2
Completed NCT03472287 - To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB) Phase 1
Withdrawn NCT01528306 - A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa Phase 2
Completed NCT02178969 - Short Term Observational Study in DEB Patients
Withdrawn NCT04214002 - The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)
Recruiting NCT04757727 - Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)
Withdrawn NCT01768026 - Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa N/A
Completed NCT01538862 - Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa N/A
Completed NCT03183934 - A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial
Completed NCT02579369 - Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa Phase 1/Phase 2
Withdrawn NCT02004600 - Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB N/A
Completed NCT04491604 - Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB Phase 3
Not yet recruiting NCT05529134 - Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene Phase 1/Phase 2
Not yet recruiting NCT04173650 - MSC EVs in Dystrophic Epidermolysis Bullosa Phase 1/Phase 2